文献速递心力衰竭与心肌病心律失常

个性化加速起搏对射血分数保留心衰患者生活质量、体力活动与房颤的影响:myPACE随机临床试验

Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

本研究为盲法随机临床试验,纳入107例B/C期射血分数保留心衰(HFpEF)且已植入起搏器患者,比较个性化加速备用起搏频率与常规60次/分。随访1年,个性化加速起搏组明尼苏达心衰生活质量问卷评分改善,NT-proBNP水平、体力活动及设备检测房颤均优于常规组,不良临床事件较少。

要点

  • 个性化加速起搏可改善HFpEF起搏器患者的生活质量与体力活动。
  • 该策略降低NT-proBNP水平并减少设备检测的房颤发生。
  • 个性化加速起搏在1年随访中安全性良好。

核心结论

  • 在HFpEF且植入起搏器患者中,适度加速的个性化起搏频率安全,并较常规60次/分设置改善生活质量、NT-proBNP水平、体力活动和房颤。

研究设计与样本

  • 盲法随机临床试验,纳入佛蒙特大学医学中心起搏器门诊2019年6月至2020年11月的B期和C期HFpEF患者,共107例随机分配至个性化加速起搏组(n=50)或常规治疗组(n=57),随访1年,采用改良意向性分析。

主要发现

  • 1年随访中,个性化加速起搏组起搏器检测心率中位数(IQR)为75(75-80)次/分,常规治疗组为65(63-68)次/分。
  • 个性化加速起搏组MLHFQ评分从基线中位数(IQR)26(8-45)降至1个月15(2-25)、1年9(4-21),P<.001;常规治疗组从基线19(6-42)升至1个月23(5-39)、1年27(7-52),P=.03。
  • 个性化加速起搏组NT-proBNP平均(SD)下降109(498)pg/dL,常规治疗组升高128(537)pg/dL,P=.02。
  • 个性化加速起搏组体力活动平均(SD)增加47(67)分钟/天,常规治疗组减少22(35)分钟/天,P<.001。
  • 设备检测房颤相对风险降低27%(P=.04);不良临床事件在个性化加速起搏组发生4例,常规治疗组11例。

临床怎么用

  • 对于已植入起搏器的HFpEF患者,可考虑采用基于身高和射血分数计算的个性化加速备用起搏频率,而非常规60次/分设置。

局限性

  • 研究为单中心试验,样本量107例,结果外推需谨慎。
  • 随访时间仅1年,长期获益与安全性未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with heart failure with preserved ejection fraction (HFpEF) with a pacemaker may benefit from a higher, more physiologic backup heart rate than the nominal 60 beats per minute (bpm) setting. OBJECTIVE: To assess the effects of a moderately accelerated personalized backup heart rate compared with 60 bpm (usual care) in patients with preexisting pacemaker systems that limit pacemaker-mediated dyssynchrony. DESIGN, SETTING, AND PARTICIPANTS: This blinded randomized clinical trial enrolled patients with stage B and C HFpEF from the University of Vermont Medical Center pacemaker clinic between June 2019 and November 2020. Analysis was modified intention to treat. INTERVENTIONS: Participants were randomly assigned to personalized accelerated pacing or usual care and were followed up for 1 year. The personalized accelerated pacing heart rate was calculated using a resting heart rate algorithm based on height and modified by ejection fraction. MAIN OUTCOMES AND MEASURES: The primary outcome was the serial change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) score. Secondary end points were changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, pacemaker-detected physical activity, atrial fibrillation from baseline, and adverse clinical events. RESULTS: Overall, 107 participants were randomly assigned to the personalized accelerated pacing (n = 50) or usual care (n = 57) groups. The median (IQR) age was 75 (69-81) years, and 48 (48%) were female. Over 1-year follow-up, the median (IQR) pacemaker-detected heart rate was 75 (75-80) bpm in the personalized accelerated pacing arm and 65 (63-68) bpm in usual care. MLHFQ scores improved in the personalized accelerated pacing group (median [IQR] baseline MLHFQ score, 26 [8-45]; at 1 month, 15 [2-25]; at 1 year, 9 [4-21]; P < .001) and worsened with usual care (median [IQR] baseline MLHFQ score, 19 [6-42]; at 1 month, 23 [5-39]; at 1 year, 27 [7-52]; P = .03). In addition, personalized accelerated pacing led to improved changes in NT-proBNP levels (mean [SD] decrease of 109 [498] pg/dL vs increase of 128 [537] pg/dL with usual care; P = .02), activity levels (mean [SD], +47 [67] minutes per day vs -22 [35] minutes per day with usual care; P < .001), and device-detected atrial fibrillation (27% relative risk reduction compared with usual care; P = .04) over 1-year of follow-up. Adverse clinical events occurred in 4 patients in the personalized accelerated pacing group and 11 patients in usual care. CONCLUSIONS AND RELEVANCE: In this study, among patients with HFpEF and pacemakers, treatment with a moderately accelerated, personalized pacing rate was safe and improved quality of life, NT-proBNP levels, physical activity, and atrial fibrillation compared with the usual 60 bpm setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04721314.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Infeld, Wahlberg, Cicero, et al. Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 36723919. doi:10.1001/jamacardio.2022.5320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。